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Background: Adjuvant chemotherapy (ACT) is known to im-
prove survival in patients with early-stage non-small cell lung
cancer. Herein, we describe chemotherapy regimens used, dose
modifications, survival, and treatment-related toxicity in the
general population.
Methods: All cases of non-small cell lung cancer diagnosed in
Ontario in the period 2004–2006 who underwent surgical resection
(n 3354) were identified using the Ontario Cancer Registry in this
population-based retrospective cohort study. We linked electronic
records of treatment to the registry to identify all cases treated with
ACT (n  1032) and describe drugs, regimens, and dosages deliv-
ered. As a proxy measure of ACT-related toxicity, we evaluated
deaths and hospitalizations within 16 weeks of starting ACT. Factors
associated with dose modification were evaluated by logistic regres-
sion. The Cox proportional hazards model was used to describe
associations between patient-, disease-, and treatment-related factors
and survival.
Results: ACT regimens were identified for 584 of 1032 ACT cases.
Almost all cases included cisplatin- or carboplatin-based regimens
(478/584, 82%, and 99/584, 17%, respectively). The most common
regimen was a vinroelbine/cisplatin doublet (412/584, 71%); 64% of
these cases had a dose reduction or omission. Dose modification was
not associated with inferior survival on multivariate analysis.
Twelve percent of all ACT cases were admitted to hospital within 16
weeks of starting ACT, and there was a 1.6% death rate potentially
attributable to ACT. Survival of all ACT cases was comparable with
outcomes reported in clinical trials.
Conclusions: ACT regimens used, toxicity, and survival outcomes
in the general population are comparable with those reported in
clinical trials. Dose modifications used in clinical practice are not
associated with inferior survival.
KeyWords: Lung cancer, Chemotherapy, Outcomes research, Prac-
tice patterns, Comparative effectiveness.
(J Thorac Oncol. 2012;7: 559–566)
In 2004, several large randomized controlled trials (RCTs)reported that adjuvant chemotherapy (ACT) improved sur-
vival substantially for patients with resected non-small cell
lung cancer (NSCLC) compared with observation alone.1
Since then, adjuvant cisplatin-based chemotherapy has be-
come a standard for eligible patients who undergo resection
of NSCLC. Recently, we reported the uptake of ACT for
NSCLC in a population-based study in Ontario, Canada.2
ACT was widely adopted from 2004 onward and was not
associated with any increase in hospitalization rates. More-
over, survival at the population level improved after 2004
consistent with the results of clinical trials.
Within the relevant RCTs, there was significant vari-
ability in drugs used, dosages, and schedules. Based on the
landmark JBR.10 and Adjuvant Navelbine International Tri-
alists Association (ANITA) trials,3,4 together with results of
meta-analyses,5,6 a vinorelbine-cisplatin doublet has been
established as a standard regimen for use in the adjuvant
setting for NSCLC. However, the dosing schedules used in
both JBR.10 and ANITA were associated with substantial
hematological toxicity and poor compliance.7 Although re-
cent work has demonstrated improved outcomes with the
uptake of ACT in the general population,2 important ques-
tions remain regarding regimens used, toxicity, and timing of
adjuvant therapy in the “real world.” The objectives of the
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current report are to (1) describe chemotherapy drugs/regi-
mens used and treatment-related toxicity in the general pop-
ulation, and (2) explore factors associated with dose modifi-
cation and its impact on outcome. To address these
objectives, we report in detail the use of ACT among all
patients who underwent surgical resection of NSCLC in
Ontario from 2004 to 2006.
METHODS
Study Design and Population
This report represents a substudy of a larger population-
based, retrospective cohort study that compared the manage-
ment and outcome of early-stage NSCLC in the Canadian
province of Ontario before and after 2004.2 Ontario has a
population of approximately 11.4 million people and a single-
payer universal health insurance program. The primary study
population included all incident cases of NSCLC diagnosed
in Ontario from 2001 to 2006 who underwent surgical resec-
tion within 24 weeks of diagnosis. Cases treated with preop-
erative radiotherapy (RT) and/or neoadjuvant chemotherapy
(both defined as treatment given between dates of diagnosis
and surgery) were excluded. Detailed methods and primary
results have been reported previously.2 In an effort to de-
scribe administration of ACT in the contemporary era, this
report includes all cases diagnosed during the period 2004–
2006 (n  3354); unless otherwise specified, all results
pertain to cases diagnosed within this time period.
Data Sources
The Ontario Cancer Registry (OCR) is a passive, pop-
ulation-based cancer registry that captures diagnostic and
demographic information on at least 98% of all incident cases
of cancer diagnosed in the province of Ontario.1,8,9 The OCR
provided the following information: International Classifica-
tion of Disease (ICD), version 9 code; the ICD for Oncology
histology code; age, sex, place of residence; and date of
death. Complete information about vital status was available
up to October 2008. The OCR does not compile information
about extent of disease or treatment. Indicators of the socio-
economic status of the community in which patients resided
at time of diagnosis were linked to the OCR as described
previously.10 Quintiles (Q) of the median household income
were based on the household income distribution for the full
province of Ontario. Q1 represents the communities where
the poorest 20% of the Ontario population resided.
A variety of electronic administrative health databases
were linked to the OCR. Records of hospitalization from the
Canadian Institute for Health Information provided informa-
tion about surgical interventions and hospital care. Hospital
participation in collection of separation records is known to
be consistent and complete throughout Ontario.11 Physicians
in Ontario submit billing codes for chemotherapy to the
Ontario Health Insurance Plan (OHIP) for remuneration.
Physician billing codes for chemotherapy from the OHIP
database were linked to the study database allowing us to
identify which patients received chemotherapy (but not the
drug/regimen name) and the date of treatment for all patients
in the province. The clinical databases of Ontario’s eight
comprehensive Regional Cancer Centers (RCCs) and Prin-
cess Margaret Hospital (PMH) provided detailed records of
chemotherapy (including drug and dose) and RT delivery.
Most of the chemotherapy records at RCCs/PMH were cap-
tured automatically at the point of prescription through the
centers’ electronic chemotherapy ordering systems and were,
therefore, of high quality. Because a substantial proportion of
chemotherapy (50%) is delivered by medical oncologists
who are not associated with RCCs/PMH, chemotherapy phy-
sician billing codes (as described earlier) were used to de-
scribe, in general terms, the use of ACT among all patients in
Ontario. RCC/PMH centers are the only providers of RT in
the province. Stage of disease at diagnosis is only captured
routinely for patients seen at RCCs. The study was approved
by the Research Ethics Board of Queen’s University.
Definitions of Comorbidity, Management, and
Outcomes
Comorbidity was classified using the Charlson Index
modified for administrative data based on all noncancer
diagnoses recorded on any hospital admission within 5 years
before surgery.12,13 Surgical resection was defined as pneu-
monectomy, lobectomy, or segmentectomy. Adjuvant ther-
apy was defined as any chemotherapy or RT administered
within 16 weeks after surgery.
As a surrogate for treatment-related toxicity, we used
the Canadian Institute for Health Information database to
identify all admissions to hospital (and their related ICD
diagnoses) within 16 weeks of starting ACT. Admissions that
were associated with ICD diagnoses of metastatic disease
(i.e., metastases, pathologic fracture, and spinal cord com-
pression) were excluded. ICD diagnostic codes for common
chemotherapy-related toxicities were grouped into infectious,
gastrointestinal, cardiac, fluid/electrolyte abnormalities, non-
infectious respiratory, anemia, and venous thromboembolism
categories. Deaths that were potentially related to ACT were
defined as any death that occurred within 16 weeks of starting
ACT that was not associated with any hospitalization ICD
diagnostic code of metastatic disease as described earlier.
For each patient, an initial chemotherapy regimen was
identified based on the first combination of drugs adminis-
tered. Subsequent regimens within the 16-week time frame
were classified as modified adjuvant regimens. Changes to
drug dose were identified by change in dosage for any
cytotoxic agent administered within 24 weeks of initiating
ACT. Dose reductions were defined as a decrease in any one
of the cytotoxic drugs administered, and omitted doses were
identified by any treatment record with a dose of zero. Details
related to carboplatin dosing were not included in this anal-
ysis as each treatment is dosed on individual creatinine
clearance and therefore dose changes were less likely to
reflect true dose modifications.
Statistical Analysis
Comparisons of proportions between study groups
were made using the 2 test. Overall survival was determined
from date of surgery using the Kaplan-Meier technique and
comparisons between groups were made using the log-rank
test. For comparative purposes, we reproduced survival
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curves from the relevant meta-analyses6,14 by measuring
survival at regular intervals on the published plots. Factors
associated with dose modification were evaluated were eval-
uated by logistic regression. Variables with p  0.1 in
univariate analysis were entered into the multivariate analy-
sis. A stepwise selection technique was used with a signifi-
cance level for entry and exit of p  0.1. Predictors were
considered statistically significant at p  0.05. The Cox
proportional hazards model was used to describe associations
between patient-, disease-, and treatment-related factors and
survival. All analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC).
RESULTS
Patterns of Care
As reported previously,2 there was substantial uptake of
ACT for NSCLC in Ontario from 2004 onward. Within the
2001–2006 study cohort (n  6304), we identified 1224
patients (19%) who received ACT. ACT was primarily used
in the postadoption cohort: 7% (192/2950) in 2001–2003
versus 31% (1032/3354) in 2004–2006 (p  0.0001). During
this study period, 4-year survival of all surgical cases (i.e.,
n  6304) improved from 52.5% in 2001–2004 to 56.1% in
2004–2006 (p  0.001). To describe use of ACT in the
postadoption period, subsequent results pertain to cases di-
agnosed in 2004–2006 (n  3354).
As shown in Figure 1, patients were identified as
having ACT using two distinct chemotherapy data sources:
OHIP physician billing records (n  1008) and treatment
records from RCCs/PMH (n  597). Among the 597 cases
identified as being treated with ACT at RCCs/PMH, we
identified corresponding physician billing records for ACT in
573 (96%), suggesting that billing records for chemotherapy
are very complete.
Characteristics related to the study population are de-
scribed in Table 1. Among the 1032 patients who received
ACT, 597 were treated at RCCs/PMH and 437 were treated
outside a comprehensive cancer center. Compared with pa-
tients who did not receive ACT, those that received ACT
were younger in age and had less comorbidity. The apparent
difference in stage distribution observed between the two
groups is likely confounded by the greater proportion of cases
with ACT referred to a RCC. TNM stage is captured rou-
tinely only for cases seen at RCCs.
Delivery of ACT
Details regarding regimens used among cases diag-
nosed during the period 2004–2006 are shown in Table 2.
Among the 597 cases with RCCs/PMH treatment records, a
regimen name was identified in 98% (584/597). Almost all
cases included cisplatin- or carboplatin-based regimens (478/
584, 82%, and 99/584, 17%, respectively). Consistent with
the relevant RCTs, the most common regimen was a vinro-
elbine/cisplatin doublet (412/584, 71%). In only a small
proportion of cases (29/584, 6%) was the initial regimen
changed. In many of these cases (10/29, 34%), the change in
regimen reflected the substitution of carboplatin for cisplatin.
Among the 520 cases with drug dosages available for
comparison, 56% of cases had at least one dose reduction or
omission. Among patients treated with vinorelbine-cisplatin,
64% of cases had a dose reduction or omission. As shown in
Table 3, the only variable independently associated with dose
modifications was region of residence.
Outcomes
As previously reported,2 the proportion of all cases
admitted to hospital within 6 months of surgery did not
change from 2001–2003 (36%) to 2004–2006 (37%), sug-
gesting that there was no major increase in serious toxicity
with the uptake of ACT. Among the 1032 cases that received
ACT in 2004–2006, 16% (160/1032) were admitted to hos-
pital with any diagnosis within 16 weeks of starting ACT;
12% (122/1032) of cases were admitted to hospital during the
same time frame when hospitalizations associated with diag-
nostic codes for metastatic disease were excluded from the
analysis. Among the latter cohort, the following diagnoses
were commonly reported: infectious (65/122, 53%); gastro-
FIGURE 1. Identification of cases
administered adjuvant chemother-
apy (ACT) among all surgical cases
of NSCLC diagnosed in Ontario
2004–2006 (n  3354).-
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intestinal (37/122, 30%); cardiac (33/122, 27%); fluid/elec-
trolyte abnormalities (26/122, 21%); noninfectious respira-
tory (24/122, 20%); anemia (23/122, 19%); and venous
thromboembolism (15/122, 12%).
Among the 1032 cases treated with ACT, there was a
3.1% (32/1032) death rate within 16 weeks of starting ACT;
half of these (16/32) deceased cases had hospitalizations
associated with ICD diagnostic codes for metastatic disease.
This translates into a death rate that is potentially attributable
to ACT of 1.6% (16/1032).
The survival curves shown in Figure 2 suggest that the
outcome of those cases treated with adjuvant vinorelbine-
cisplatin in the general population are very comparable with
survival of patients from clinical trials as reported in two
large meta-analyses.6,14 The Cox analyses (Table 4) suggest
that increased comorbidity, advanced stage of disease, and
more extensive surgery are independently associated with
worsened survival. Squamous cell histology was associated
with improved survival. Dose modification was not found to
be associated with inferior survival.
DISCUSSION
Clinical trials reported in 2004 led to substantial uptake
of ACT in the Canadian province of Ontario. In this report,
we describe details about what, how, and when ACT was
administered in the “real world.” From this large population-
based study, several important findings have emerged. First,
it is reassuring that the predominant regimen used in Ontario
in the period 2004–2006 is vinorelbine-cisplatin for which
the strongest clinical trial evidence exists. Second, compati-
ble with the clinical trials, a substantial proportion of cases in
the general population undergo dose and drug regimen mod-
ifications. Third, dose modification of ACT does not appear
to be associated with inferior survival. Fourth, rates of hos-
pitalization and death potentially attributable to ACT are
consistent with those reported in RCTs. Finally, the survival
of patients treated with ACT in the general population is
comparable with survival of patients in clinical trials, lending
further support to the effectiveness of therapy.
TABLE 1. Characteristics of Patients Diagnosed with Non-
small Cell Lung Cancer in Ontario 2004–2006 Who
Underwent Surgical Resection (n  3354)
Characteristic
All Cases Who
Underwent Surgery
ACT
n  1032 (31%)
No ACT
n  2322 (69%)
no. (%)a
Patient-related
Age, years
20–49 100 (56) 80 (44)
50–59 293 (49) 308 (51)
60–69 398 (37) 680 (63)
70–79 229 (19) 996 (81)
80 12 (4) 258 (96)
Sex
Male 515 (30) 1203 (70)
Female 520 (32) 1119 (68)
SES, quintileb
1 204 (29) 513 (72)
2 274 (35) 509 (65)
3 212 (30) 506 (71)
4 176 (30) 427 (71)
5 164 (31) 365 (69)
Charlson co-morbidity score
0 821 (33) 1639 (67)
1–2 192 (25) 572 (75)
3 19 (15) 111 (85)
Disease-related
Histology
Adenocarcinoma 558 (31) 1272 (70)
Squamous carcinoma 298 (29) 720 (71)
Large cell carcinoma 23 (32) 49 (68)
Mixed 37 (36) 65 (64)
Carcinoma NOS 116 (35) 216 (65)
Pathologic stage
I 209 (36) 372 (64)
II 185 (66) 96 (34)
III 131 (61) 84 (39)
IV 48 (38) 80 (63)
Unknown 459 (21) 1690 (79)
Treatment-related
Surgery
Pneumonectomy 187 (47) 211 (53)
Lobectomy 600 (30) 1407 (70)
Segmentectomy 245 (26) 704 (74)
Median LOS following surgery 6 days 7 days
Referral to Regional Cancer Center 736 (40) 1084 (60)
aPercentages reflect proportion of cases in each category that had ACT. Percentages
may not add to 100% due to rounding. Abbreviations: SES, socioeconomic status; NOS,
not otherwise specified; LOS, length of stay
bSES quintile 1 represents patients from the poorest communities in Ontario.
TABLE 2. ACT Regimens Administered to 584 Cases
Treated at RCCs/PMH from 2004 to 2006
Frequencya
Use of cisplatin/carboplatinb
Cisplatin-based 478 (82%)
Carboplatin-based 99 (17%)
No cisplatin or carboplatin 7 (1%)
Specific regimensb
Vinorelbine/cisplatin 412 (71%)
Vinorelbine/carboplatin 27 (5%)
Carboplatin/paclitaxel 55 (9%)
Etoposide/cisplatin 45 (8%)
Other 45 (8%)
Regimen modification
Change in drugs used 29 (6%)
Dose reductionc 144/520 (28%)
Omitted dosec 147/520 (28%)
a Denominator is 584 unless otherwise noted.
b Refers to regimen used in first cycle of ACT.
c Dose reduction and omitted doses were evaluated among the 520 cases for which
drug dosage were identifiable from existing data sources.
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TABLE 3 Variables Associated with Dose Modification of Adjuvant Chemotherapy (ACT) for Non-Small Cell Lung Cancer
Among 520 Cases with Bose Records Available Diagnosed in Ontario 2004–2006
Characteristic
Proportion Cases with
Dose Modification
Univariate Analysis Multivariate Analysis
OR (95%CI) P Value OR (95%CI) P Value
Patient-related
Sex
Male (n  270) 56% Ref — —
Female (n  250) 56% 0.97 (0.69–1.38) 0.873 — —
Age, years
20–49 (n  53) 55% Ref — —
50–59 (n  144) 56% 1.03 (0.55–1.95) 0.916 — —
60–69 (n  209) 57% 1.12 (0.61–2.05) 0.723 — —
70 (n  114) 54% 0.99 (0.51–1.90) 0.968 — —
Socioeconomic status, quintile
1 (n  121) 55% Ref — —
2 (n  144) 53% 0.93 (0.57–1.51) 0.774 — —
3 (n  97) 61% 1.29 (0.75–2.23) 0.352 — —
4 (n  83) 57% 1.09 (0.62–1.91) 0.769 — —
5 (n  75) 57% 1.12 (0.63–2.00) 0.703 — —
Charlson co-morbidity score
0 (n  414) 54% Ref — —
1–2 (n  96) 64% 1.48 (0.94–2.34) 0.094 — —
3 (n  10) 60% 1.27 (0.35–4.58) 0.712 — —
Disease-related
Histology
Adenocarcinoma (n  268) 53% Ref — —
Squamous carcinoma (n  164) 61% 1.39 (0.93–2.06) 0.105 — —
Large cell carcinoma (n  13) 69% 2.00 (0.60–6.64) 0.260 — —
Mixed (n  12) 67% 1.78 (0.52–6.04) 0.358 — —
Carcinoma NOS (n  63) 51% 0.92 (0.53–1.59) 0.754 — —
Pathologic stage
I (n  162) 61% Ref — —
II (n  149) 51% 0.66 (0.42–1.04) 0.073 — —
III (n  98) 58% 0.89 (0.53–1.47) 0.638 — —
IV (n  26) 50% 0.64 (0.28–1.46) 0.287 — —
Unknown (n  85) 54% 0.75 (0.44–1.28) 0.290 — —
Treatment-related
Surgery
Lobectomy (n  336) 55% Ref — —
Pneumonectomy (n  91) 63% 1.40 (0.87–2.26) 0.164 — —
Segmentectomy (n  93) 55% 1.02 (0.64–1.61) 0.949 — —
Length of hospital stay
Median (n  283) 57% 1.12 (0.79–1.59) 0.520 — —
Median (n  237) 54% Ref — —
Geographic region of Ontario
A (n  64) 44% Ref Ref
B (n  87) 58% 1.74 (0.91–3.33) 0.097 1.74 (0.91–3.33) 0.096
C (n  98) 47% 1.14 (0.60–2.14) 0.691 1.14 (0.60–2.14) 0.691
D (n  70) 73% 3.45 (1.68–7.11) 0.001 3.45 (1.68–7.11) 0.001
E (n  29) 66% 0.63 (0.38–1.03) 0.055 0.63 (0.38–1.03) 0.055
F (n  31) 39% 0.81 (0.34–1.95) 0.641 0.81 (0.34–1.95) 0.641
G (n  35) 54% 1.53 (0.67–3.50) 0.317 1.53 (0.67–3.50) 0.317
H (n  106) 62% 2.12 (1.13–3.99) 0.020 2.12 (1.13–3.99) 0.020
Note: Percentages may not add to 100% due to rounding.
Abbreviations: RR, relative risk; Ref, reference group; SES, socioeconomic status; NOS, not otherwise specified.
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Contemporary RCTs which established the role of ACT
for NSCLC include IALT, NCIC CTG JBR.10, the ANITA
trial, and Cancer and Leukemia Group B (CALGB) 9633.1
Adjuvant vinorelbine-cisplatin led to improved outcomes in
both JBR.10 and the ANITA trial, with absolute improve-
ments in survival of 15% and 9% at 5 years, respectively.3,4
Both trials used a 28-day regimen in which patients where
given 25 to 30 mg/m2 of vinorelbine weekly and 100 mg/m2
of cisplatin per cycle. In JBR.10, cisplatin was given in two
divided doses on days 1 and 8. These regimens were
associated with substantial hematologic toxicity with most
of patients experiencing dose reductions and/or omissions.
Only 50% (108/215) of patients in JBR.10 completed four
cycles of therapy, and 77% had at least one dose reduction
or omission.3,7 It is important to note that the impressive
survival benefit in both JBR.10 and ANITA was seen
despite the relatively high rates of hematologic toxicity
and low-dose delivery.
Data from this study suggest that dose modification is
also common among patients in the general population. The
rate of dose reductions and omissions in the general popula-
tion is comparable to figures reported in JBR.10. However,
limitations of existing treatment records in our population-
based study may lead to an underestimation of dose omis-
sions. In any case, we have observed comparable outcomes in
the general population despite frequent dose reductions and
omissions.
CALGB 9633 evaluated paclitaxel and carboplatin in
patients with stage IB disease. Although initial results pre-
sented in 200415 showed a 12% absolute improvement in
survival at 4 years, when mature data were presented in 2006
the difference was no longer statistically significant.16,17 We
did observe that a substantial number of patients were treated
with carboplatin-paclitaxel during the study period when
existing evidence supported use of this regimen. Ongoing
research will explore whether use of adjuvant carboplatin-
paclitaxel declined after updated results of CALGB 9633
were presented in 2006. Our data also suggest that carbopla-
tin is used in the general population as a substitute for
cisplatin (25 patients received vinorelbine-carboplatin). It is
likely that this reflects treatment of patients with renal insuf-
ficiency, hearing deficits, or neuropathy who would not be
eligible for cisplatin. These patients routinely are excluded
from clinical trials yet represent a sizable proportion of
patients in the general population. Further work is needed to
identify whether these patients benefit from ACT and what
regimens should be used.
As reported previously,2 the proportion of NSCLC
surgical cases admitted to hospital did not increase from
2001–2003 to 2004–2006, coincident with the adoption of
ACT suggesting no major increase in patient toxicity. Among
the 1032 cases treated with ACT in 2004–2006, we observed
rates of hospitalization (12%) and death (1.6%) that are very
comparable to those reported in the ACT arm of JBR.10
(19% hospitalization; 0.9% death rate) and ANITA (hospi-
talization not reported; 2% death rate).3,4
Translation of knowledge from RCTs into societal
benefit relies on the novel therapy being adopted by practi-
tioners and whether the results of the clinical trial are gener-
alizable to the overall population. Because patients, physi-
cians, and concurrent care in the general population may be
very different from the controlled context of a clinical trial, it
is essential that we not assume that the benefits demonstrated
in phase 3 studies will be fully realized at the population
level. It is therefore reassuring that the survival of patients
treated in the general population is very comparable to
survival observed in the relevant clinical trials. Although
RCTs have clearly established efficacy for ACT in NSCLC,
this population-based study lends support to the effectiveness
of ACT in the “real world.”
Although this study is the largest and first comprehen-
sive report to provide detailed-treatment information for pa-
tients administered ACT in the general population, several
methodologic limitations merit comment. Although the data
sources used in this study describe general aspects of disease,
treatment, and outcome for all patients in Ontario, detailed
information related to chemotherapy administration, treat-
ment toxicity, performance status, and stage of disease is not
available for all patients. This limits our ability to evaluate
the appropriateness of case selection for ACT and also makes
it difficult to determine with certainty the relationship be-
tween time from surgery to initiation of ACT and outcome.
Incomplete records regarding dosing of ACT have limited our
ability to provide detailed information on dose intensity and
its impact on outcome. Furthermore, treatment details related
to drug regimen and dose are only available for those patients
treated at a RCC and therefore may not represent practice at
hospitals not affiliated with a cancer center. Finally, we have
used rates of hospitalization as a surrogate for the most
serious toxicity related to ACT. Trends in rates of hospital-
ization may be confounded by changes of practice regarding
in-patient care and greater use of community resources.
FIGURE 2. Reported survival of NSCLC cases treated with
vinorelbine-cisplatin adjuvant chemotherapy.
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In addition to its very large sample size and resulting
statistical power, a major strength of the current study is the
fact that by virtue of the OCR, our study population includes
all cases of NSCLC within Ontario and is therefore unse-
lected. By including the entire population of interest, it is
possible to minimize the referral and selection biases that
plague traditional institution-based observational studies.18 In
fact, we describe use of ACT among 1032 patients in Ontario
and have detailed records for the 584 cases treated at com-
prehensive cancer centers. This represents a large sample of
patients when one considers that 242 and 407 patients were
randomized to receive ACT in the JBR.10 and ANITA trials,
respectively.
In summary, the outcomes associated with ACT for
NSCLC in the general population are comparable to those
reported in clinical trials. It is reassuring that the rates of
hospitalization and on-treatment mortality in the general
population are not substantially different from those reported
TABLE 4 Variables Associated with Survival Among 1032 Patients with Non-Small Cell Lung Cancer Treated with Adjuvant
Chemotherapy in Ontario 2004–2006
Characteristic OS at 4 Years
Univariate Analysis Multivariate Analysis
HR (95%CI) P Value HR (95%CI) P Value
Patient-related
Sex
Male (n  515) 55% Ref Ref
Female (n  517) 60% 0.78 (0.63–0.95) 0.015 0.82 (0.66–1.02) 0.070
Age, years
20–49 (n  100) 60% Ref Ref
50–59 (n  293) 62% 0.82 (0.56–1.20) 0.316 0.86 (0.59–1.26) 0.433
60–69 (n  398) 57% 0.95 (0.66–1.36) 0.758 0.92 (0.63–1.33) 0.651
70 (n  241) 52% 1.16 (0.80–1.69) 0.442 1.17 (0.79–1.73) 0.427
Socioeconomic status, quintile
1 (n  204) 58% Ref Ref
2 (n  274) 57% 1.02 (0.76–1.37) 0.895 1.02 (0.75–1.37) 0.924
3 (n  212) 53% 1.04 (0.76–1.41) 0.828 1.05 (0.77–1.44) 0.747
4 (n  176) 58% 0.93 (0.67–1.30) 0.680 0.90 (0.64–1.26) 0.536
5 (n  164) 64% 0.88 (0.62–1.25) 0.474 0.80 (0.56–1.14) 0.221
Charlson co-morbidity score
0 (n  821) 58% Ref Ref
1–2 (n  192) 55% 1.18 (0.92–1.52) 0.205 1.18 (0.91–1.53) 0.214
3 (n  19) 42% 2.00 (1.09–3.64) 0.025 2.10 (1.14–3.88) 0.018
Disease-related
Histology
Adenocarcinoma (n  558) 56% Ref Ref
Squamous carcinoma (n  298) 63% 0.93 (0.73–1.18) 0.528 0.74 (0.57–0.95) 0.021
Large cell carcinoma (n  23) 46% 1.20 (0.64–2.27) 0.567 1.24 (0.65–2.36) 0.509
Mixed (n  37) 54% 1.16 (0.68–2.00) 0.588 1.00 (0.58–1.73) 0.997
Carcinoma NOS (n  116) 55% 1.37 (1.00–1.86) 0.049 1.12 (0.81–1.54) 0.490
Pathologic stage
I (n  209) 75% Ref Ref
II (n  185) 48% 2.29 (1.59–3.29) 0.001 2.17 (1.50–3.14) 0.001
III (n  131) 46% 2.67 (1.82–3.91) 0.001 2.33 (1.58–3.44) 0.001
IV (n  48) 31% 5.52 (3.50–8.72) 0.001 4.89 (3.04–7.88) 0.001
Unknown (n  459) 59% 1.73 (1.24–2.40) 0.001 1.48 (1.02–2.14) 0.038
Treatment-related
Surgery
Lobectomy (n  600) 60% Ref Ref
Pneumonectomy (n  187) 50% 1.62 (1.26–2.1) 0.001 1.52 (1.17–1.99) 0.002
Segmentectomy (n  245) 57% 1.1 (0.85–1.40) 0.518 0.96 (0.74–1.24) 0.762
ACT dose modification
No dose modification (n  229) 62% Ref Ref
Dose modification (n  291) 57% 1.06 (0.79–1.42) 0.719 1.07 (0.80–1.44) 0.651
Unknown (n  512) 56% 1.09 (0.83–1.41) 0.566 1.21 (0.88–1.66) 0.242
Abbreviations: OS, overall survival; HR, hazard ratio; Ref, reference group; SES, socioeconomic status; NOS, not otherwise specified; ACT, adjuvant chemotherapy.
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in RCTs. Furthermore, although dose modifications of ACT
are common, they do not seem to be associated with inferior
outcome. Further research is needed to identify appropriate-
ness of ACT utilization in the general population.
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